Kudos to client and biotechnology company Ventoux Biosciences on securing a U.S. patent covering methods of treating immune-fibrotic disorders, including Dupuytren’s disease. The patent is the latest addition to Ventoux’s strategically crafted intellectual property portfolio. This victory follows success from last year, when the privately held company achieved a breakthrough in pre-clinical trials for a new treatment of fibrosis while launching a new funding round.

The new patent was secured quickly using the U.S. Patent and Trademark Office’s Prioritized Patent Examination Program, known as Track One, under the guidance of Procopio Partner and Life Sciences Co-Leader Xiaofan “Frank” Yang, PhD.

“This is a major milestone for Ventoux Biosciences,” said Kurt Harrington, Ventoux CEO and a patient living with Dupuytren’s disease. “It validates our novel approach to targeting the drivers of fibrosis and underscores our commitment to bringing transformative therapies to patients. For too long, individuals with Dupuytren’s and related conditions have had few options. We believe our platform has the potential to deliver meaningful, disease-modifying outcomes.”

Dupuytren’s disease is more than four times more common than rheumatoid arthritis and affects millions worldwide. Despite its prevalence and impact on hand function and quality of life, there are no approved disease-modifying therapies. Ventoux addresses the underlying biological pathways that drive fibrosis.

For more details on the innovation recognized by the USPTO with a patent, and Ventoux Biosciences, read their press release and visit their website.